Company Overview

PRIME exits and American Healthcare Capital are proud to be the exclusive representative of a Clinical Research Company for sale. This opportunity involves the sale of a well-established Clinical Trial Site Management Organization headquartered in a major metropolitan area in Texas. Operating since 2006, the company provides clinical trial management services to pharmaceutical companies. With consistent revenue growth, a diversified client base, and robust operational infrastructure, this business is ideal for strategic or financial buyers looking to expand in the clinical research sector.

Key Highlights:

•           Long-standing industry reputation with nearly two decades of experience.

•           Growing Revenue and Profit Margin.

•           Approximately 25 active clients and a scalable operational model.

•           Owned real estate associated with operations, offering long-term stability.

•           Staff includes 8-10 full-time employees and 6-8 contract employees.

•           Growth potential through expanded geographic reach and expansion to additional therapeutic areas.

Financial Highlights

The company demonstrated a steady growth trajectory, driven by strong client relationships and an expanding market. Gross revenue was over $800,000 in 2024 with an adjusted EBITDA of nearly $455,000. They are projected to reach $925,000 in 2025 with an adjusted EBITDA of $525,000.

The company’s consistent revenue growth is a direct result of its strong referral network and ongoing industry demand for reliable clinical trial management services.

Reason for Sale

The primary owner is seeking to retire after building a successful and reputable business. The Seller is open to staying involved with the business for a mutually agreed time and phase out toward full retirement.

Asking Price and Valuation Guidance

The asking price for this opportunity is $3.5 million. The price excludes working capital, inventory, cash, accounts receivables, or the real estate The Seller will consider all reasonable offers and may be open to idea of rolled equity with an experienced and a suitable partner